MedTrace Logo

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

NCT05855941 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-12-16

No results posted yet for this study

Summary

The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:

* Does advanced medical imaging predict survival?
* Can advanced medical imaging improve radiotherapy target planning?
* Are advanced medical imaging results associated with risk markers found in tumor tissue?

Participants will

* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months.
* Be subject to clinical follow-up for five years.

Conditions

Interventions

DIAGNOSTIC_TEST

FDG-PET/CT and FDG-PET/MRI

Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.

Sponsors & Collaborators

  • Umeå University

    collaborator OTHER

  • Region Västerbotten

    lead OTHER_GOV

Principal Investigators

  • Sara Strandberg, MD, PhD · Department of Radiation Sciences, Umea University/Radiology, Umea University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-23
Primary Completion
2032-05-31
Completion
2032-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05855941 on ClinicalTrials.gov